A better technology or drug supplants its predeces
Post# of 72440
IPIX is not in third place. It is neck and neck for first to market, but even if a less-effective drug that requires IV to work makes it to market first, a superior, cheaper (no doctor's office visits needed for IV) and more efficacious oral rinse is going to be the drug of choice.
What insurer wants to pay for a treatment that isn't very good, requires that the person have IVs for administration, and also is going to affect them systemically, when they can just do a convenient oral rinse at home -- with no systemic absorption?